Propranolol Therapeutic Cheat Sheet
Propranolol, a nonselective β-adrenergic blocker introduced in the 1960s, remains a cornerstone therapy in cardiology for hypertension, angina, and migraine prophylaxis. It has since gained transformative use in dermatology following the serendipitous discovery of its efficacy in infantile hemangiomas (IH), becoming the first FDA-approved systemic therapy for proliferating IH in 2014 given its va …
Propranolol, a nonselective β-adrenergic blocker introduced in the 1960s, remains a cornerstone therapy in cardiology for hypertension, angina, and migraine prophylaxis. It has since gained transformative use in dermatology following the serendipitous discovery of its efficacy in infantile hemangiomas (IH), becoming the first FDA-approved systemic therapy for proliferating IH in 2014 given its va … 
An 18 year old female presents with the following rash. The patient notes the rash is mildly itchy and occurs monthly in the same area. What is the most likely diagnosis?
A. Nummular dermatitis
B. Sweet's syndrome
C. Erythema multiforme
D. Arthropod reaction
E. Fixed drug eruption
To find out the correct answer and read the explanation, click here.
Brought to you by … 
Dr. Robyn Siperstein, a dermatologist in Boca Raton and Boynton Beach, Fla., credits a culture of service for the growth of her dermatology practice to more than 100 staff members at two locations. Next Steps in Derm, in partnership with the ODAC Dermatology Conference, interviewed Dr. Siperstein, who shared some of her early leadership lessons. Want to find more enjoyment in your work? Find out h … 
INTRODUCTION
Alopecia universalis is a type of alopecia areata (AA) characterized by total body hair loss. The mechanism of this loss is primarily due to autoimmune disruption of the hair follicle. AA has historically been treated with corticosteroids, minoxidil, and other immune therapies that possess limited efficacy with high recurrence rates and adverse effects.1 However, in recent years the … 
At the 2025 ODAC Dermatology Conference, Christina Kraus, MD, expanded on her earlier discussion of off-label topical approaches by surveying the landscape of systemic therapies for these challenging cases. Her lecture synthesized the latest evidence, highlighted patient-selection considerations, and introduced both established and emerging systemic agents—equippi …